Ospemifen

Ospemifen
Klinički podaci
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	26 h
Identifikatori
CAS broj	128607-22-7
ATC kod	G03XC05 (WHO)
PubChem	CID 3036505
DrugBank	DB04938
ChemSpider	2300501
ChEBI	CHEBI:73275
ChEMBL	CHEMBL2105395
Hemijski podaci
Formula	C24H23ClO2
Molarna masa	378,891
	SMILES OCCOC1=CC=C(C=C1)C(=C(\CCCl)C1=CC=CC=C1)\C1=CC=CC=C1; ;
	InChI InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23- ; Key:LUMKNAVTFCDUIE-VHXPQNKSSA-N ;

Ospemifen je organsko jedinjenje, koje sadrži 24 atoma ugljenika i ima molekulsku masu od 378,891 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	2
Broj donora vodonika	1
Broj rotacionih veza	8
Particioni koeficijent^[9] (ALogP)	5,6
Rastvorljivost^[10] (logS, log(mol/L))	-7,7
Polarna površina^[11] (PSA, Å²)	29,5

Reference

^ Taras TL, Wurz GT, DeGregorio MW: In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. ;77(4-5):271-9. Taras, T. L.; Wurz, G. T.; Degregorio, M. W. (2001 Jun). „In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer”. The Journal of Steroid Biochemistry and Molecular Biology. 77 (4–5): 271—279. PMID 11457665. doi:10.1016/s0960-0760(01)00066-8. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU: Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas. Voipio, S. K.; Komi, J.; Kangas, L.; Halonen, K.; Degregorio, M. W.; Erkkola, R. U. (новембар 2002). „Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women”. Maturitas. 43 (3): 207—14. PMID 12443837. doi:10.1016/s0378-5122(02)00206-2.
^ Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O: Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause. ;Rutanen, E. M.; Heikkinen, J.; Halonen, K.; Komi, J.; Lammintausta, R.; Ylikorkala, O. (2003 Sep-Oct). „Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: A double-blind, randomized trial”. Menopause (New York, N.Y.). 10 (5): 433—9. PMID 14501605. doi:10.1097/01.GME.0000063609.62485.27. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Ylikorkala O, Cacciatore B, Halonen K, Lassila R, Lammintausta R, Rutanen EM, Heikkinen J, Komi J: Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal wo men. Menopause. ;Ylikorkala, O.; Cacciatore, B.; Halonen, K.; Lassila, R.; Lammintausta, R.; Rutanen, E. M.; Heikkinen, J.; Komi, J. (2003 Sep-Oct). „Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women”. Menopause (New York, N.Y.). 10 (5): 440—7. PMID 14501606. doi:10.1097/01.GME.0000063566.84134.98. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Tolonen A, Koskimies P, Turpeinen M, Uusitalo J, Lammintausta R, Pelkonen O: Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 14:1-9.Tolonen, A.; Koskimies, P.; Turpeinen, M.; Uusitalo, J.; Lammintausta, R.; Pelkonen, O. (2013 May). „Ospemifene metabolism in humans in vitro and in vivo: Metabolite identification, quantitation, and CYP assignment of major hydroxylations”. Drug Metabolism and Drug Interactions. 28 (3): 153—161. PMID 23729558. doi:10.1515/dmdi-2013-0016. Проверите вредност парамет(а)ра за датум: |date= (помоћ).
^ McCall JL, DeGregorio MW: Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol. McCall, Jamie L.; Degregorio, Michael W. (јун 2010). „Pharmacologic evaluation of ospemifene”. Expert Opinion on Drug Metabolism & Toxicology. 6 (6): 773—9. PMID 20429673. doi:10.1517/17425255.2010.487483. ..
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Ospemifene

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Taras TL, Wurz GT, DeGregorio MW: In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. ;77(4-5):271-9. Taras, T. L.; Wurz, G. T.; Degregorio, M. W. (2001 Jun). „In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer”. The Journal of Steroid Biochemistry and Molecular Biology. 77 (4–5): 271—279. PMID 11457665. doi:10.1016/s0960-0760(01)00066-8. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[2] Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU: Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas. Voipio, S. K.; Komi, J.; Kangas, L.; Halonen, K.; Degregorio, M. W.; Erkkola, R. U. (новембар 2002). „Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women”. Maturitas. 43 (3): 207—14. PMID 12443837. doi:10.1016/s0378-5122(02)00206-2.

[3] Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O: Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause. ;Rutanen, E. M.; Heikkinen, J.; Halonen, K.; Komi, J.; Lammintausta, R.; Ylikorkala, O. (2003 Sep-Oct). „Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: A double-blind, randomized trial”. Menopause (New York, N.Y.). 10 (5): 433—9. PMID 14501605. doi:10.1097/01.GME.0000063609.62485.27. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[4] Ylikorkala O, Cacciatore B, Halonen K, Lassila R, Lammintausta R, Rutanen EM, Heikkinen J, Komi J: Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal wo men. Menopause. ;Ylikorkala, O.; Cacciatore, B.; Halonen, K.; Lassila, R.; Lammintausta, R.; Rutanen, E. M.; Heikkinen, J.; Komi, J. (2003 Sep-Oct). „Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women”. Menopause (New York, N.Y.). 10 (5): 440—7. PMID 14501606. doi:10.1097/01.GME.0000063566.84134.98. Проверите вредност парамет(а)ра за датум: |date= (помоћ)

[5] Tolonen A, Koskimies P, Turpeinen M, Uusitalo J, Lammintausta R, Pelkonen O: Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. Drug Metabol Drug Interact. 14:1-9.Tolonen, A.; Koskimies, P.; Turpeinen, M.; Uusitalo, J.; Lammintausta, R.; Pelkonen, O. (2013 May). „Ospemifene metabolism in humans in vitro and in vivo: Metabolite identification, quantitation, and CYP assignment of major hydroxylations”. Drug Metabolism and Drug Interactions. 28 (3): 153—161. PMID 23729558. doi:10.1515/dmdi-2013-0016. Проверите вредност парамет(а)ра за датум: |date= (помоћ).

[6] McCall JL, DeGregorio MW: Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol. McCall, Jamie L.; Degregorio, Michael W. (јун 2010). „Pharmacologic evaluation of ospemifene”. Expert Opinion on Drug Metabolism & Toxicology. 6 (6): 773—9. PMID 20429673. doi:10.1517/17425255.2010.487483. ..

[7] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[8] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[9] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[10] Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[11] Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]